MedTrace Logo

CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

NCT01402661 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 91758

Last updated 2025-10-02

No results posted yet for this study

Summary

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for RA in a cohort of patients cared for by rheumatologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Conditions

Sponsors & Collaborators

  • University of Massachusetts, Worcester

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • CorEvitas

    lead NETWORK

Principal Investigators

  • Joel Kremer, MD · Center for Rheumatology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2100-12-31
Completion
2100-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01402661 on ClinicalTrials.gov